All In Biotech

Drug Trial Radar · NCT07711223

Efficacy and Safety of ACC017 Tablets Compared With Dolutegravir Sodium Tablets in Treatment-Naïve Adults With Human Immunodeficiency Virus Type 1 (HIV-1)

A Multicenter, Randomized, Double-Blind, Double-Dummy, Dolutegravir Sodium Tablets Controlled, Phase III Study to Evaluate the Efficacy and Safety of ACC017 Tablets in Treatment-Naïve Adults With Human Immunodeficiency Virus Type 1 (HIV-1)

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 660 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

660

Planned (sponsor's estimate)

Start

Nov 7, 2025

Primary completion

Aug 31, 2028

Study completion Dec 31, 2028

Sponsor

Sponsor type
Industry
First posted
Jul 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study employs a multicenter, randomized, double-blind, double-dummy, active-controlled, parallel-group, non-inferiority design. The trial will be conducted in treatment-naïve adult patients with HIV-1, using Dolutegravir Sodium Tablets as the control, to demonstrate the efficacy and safety of the core investigational drug ACC017 combined with FTC/TAF Tablets (II) compared to Dolutegravir Sodium combined with FTC/TAF Tablets (II) in treating treatment-naïve adult HIV-1 patients. After initial screening eligibility is confirmed, participants will return to the clinic on Day 1 (D1) for re-evaluation of eligibility and completion of required examinations. Eligible participants will be randomized in a 1:1 ratio to receive either ACC017 Tablets (40 mg, once daily \[QD\]) or Dolutegravir Sodium Tablets (50 mg, QD). Both treatment groups will also receive FTC/TAF Tablets (II) and will undergo 48 weeks of continuous double-blind treatment. Subsequently, all study participants will transition to open-label treatment with ACC017 combined with FTC/TAF Tablets (III) for an additional 48 weeks (during which the dummy medication will no longer be administered).

Conditions

  • Infection, Human Immunodeficiency Virus

Interventions

  • ACC017+FTC/TAFDrug

    ACC017+Emtricitabine/Tenofovir Alafenamide

  • DTG+FTC/TAFDrug

    Dolutegravir+Emtricitabine/Tenofovir Alafenamide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. At 48 weeks of treatment, the percentage of participants with HIV RNA load <50 copies/mL (analyzed using the US FDA Snapshot Approach) (primary analysis).Time frame: week 48

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Ditan Hospital Capital Medical University, Beijing, China

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.